Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TIM-3 in autoimmunity.

Ana C Anderson1, David E Anderson

  • 1Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.

Current Opinion in Immunology
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state.

Immunity·2026
Same author

Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing RORγt and suppressing glucocorticoid receptor activity.

Immunity·2026
Same author

Myelin antigen-specific effector CD8+ T cells induce chronic CNS autoimmunity in a CD4+ T cell-dependent manner.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Mesenchymal Stem Cell Secretome in Tendon Regeneration: Therapeutic Potential, Mechanisms of Action, and Future Perspectives.

Cells·2026
Same author

Comparisons and Contrasts in a Complete Set of Alkali Metal Cumyl Structures.

Inorganic chemistry·2026
Same author

Degenerative Gastrocnemius Muscle Changes in a Goat Tibial Ostectomy Model Persist 10 Months After Splint Removal.

Muscles (Basel, Switzerland)·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same journal

Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection.

Current opinion in immunology·2026
See all related articles

The T cell immunoglobulin and mucin domain (TIM)-3-galectin-9 pathway regulates Th1 immunity. Dysregulation of this pathway may contribute to autoimmune diseases like multiple sclerosis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Autoimmune Diseases

Background:

  • T cell immunoglobulin and mucin domain (TIM)-3 is expressed on terminally differentiated Th1 cells.
  • Galectin-9 has been identified as a ligand for TIM-3.
  • The TIM-3-galectin-9 pathway is crucial for regulating Th1 immunity and inducing tolerance.

Purpose of the Study:

  • To investigate the role of TIM-3 in human Th1 regulation.
  • To explore the association of TIM locus and TIM-3 polymorphisms with immune-mediated diseases.
  • To examine the potential involvement of the TIM-3-galectin-9 pathway in chronic autoimmune conditions.

Main Methods:

  • Expression analysis of TIM-3 on human Th1 and Th2 cells.
  • Genetic association studies linking TIM locus and TIM-3 polymorphisms to diseases.

Related Experiment Videos

  • Analysis of the TIM-3-galectin-9 pathway in autoimmune disease models.

    • Main Results:

    • TIM-3 expression is conserved on human Th1 cells, suggesting a similar regulatory role as in mice.
    • Genetic data link the TIM locus and TIM-3 variations to immune-mediated diseases.
    • Evidence suggests that the TIM-3-galectin-9 pathway's dysregulation may underlie autoimmune diseases, including multiple sclerosis.

    Conclusions:

    • The TIM-3-galectin-9 pathway is a significant regulator of Th1 immunity in both mice and humans.
    • TIM-3 and its ligand galectin-9 represent potential therapeutic targets for autoimmune diseases.
    • Further research into this pathway could elucidate mechanisms of immune-mediated diseases and inform treatment strategies.